http://blog.bioasis.ca/?p=1589 The Science of Melanotransferrin (p97) Thu, 02 Sep 2010 15:27:11 +0000 hourly 1 http://wordpress.org/?v=3.0 http://blog.bioasis.ca/?p=1589&cpage=1#comment-313 FDA Rejects Clabridine NDA For First Multiple Sclerosis Pill Fri, 11 Dec 2009 15:07:15 +0000 http://blog.bioasis.ca/?p=1589#comment-313 [...] Idec has seen its own struggles developing Tysabri this year – from consolidation pressures to bad cases of side-effects in patients involved in clinical trials. It doesn’t seem like [...] [...] Idec has seen its own struggles developing Tysabri this year – from consolidation pressures to bad cases of side-effects in patients involved in clinical trials. It doesn’t seem like [...]

]]> http://blog.bioasis.ca/?p=1589&cpage=1#comment-179 Biogen Wins Tysabri Case – Plans To Grow By Expanding MS Pipeline | Bioasis Technologies Inc. Wed, 16 Sep 2009 15:37:00 +0000 http://blog.bioasis.ca/?p=1589#comment-179 [...] We covered this situation a couple weeks back, when Johnson and Johnson acquired 18.4% of Elan in a deal that included Elan’s Alzheimer’s pipeline and the rights to acquire all of Tysabri’s marketing rights in case Biogen was bought out by another company. Sensing that this would adversely affect its position in the market, Biogen accused Elan of violating its Tysabri agreement (since Elan had not discussed the JnJ deal with them before it was done) and asked for forfeiture of all of Tysabri rights under their previous agreement. The case went straight to federal court – Tysabri being the best-selling MS drug on the market meant Biogen could have lost a big winner, a drug that provided about half a billion dollars in revenue last year. [...] [...] We covered this situation a couple weeks back, when Johnson and Johnson acquired 18.4% of Elan in a deal that included Elan’s Alzheimer’s pipeline and the rights to acquire all of Tysabri’s marketing rights in case Biogen was bought out by another company. Sensing that this would adversely affect its position in the market, Biogen accused Elan of violating its Tysabri agreement (since Elan had not discussed the JnJ deal with them before it was done) and asked for forfeiture of all of Tysabri rights under their previous agreement. The case went straight to federal court – Tysabri being the best-selling MS drug on the market meant Biogen could have lost a big winner, a drug that provided about half a billion dollars in revenue last year. [...]

]]>